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Synaptophysin is an integral membrane protein of
synaptic vesicles characterized by four transmembrane
domains with both termini facing the cytoplasm. Al-
though synaptophysin has been implicated in neuro-
transmitter release, and decreased synaptophysin levels
have been associated with several neurodegenerative
diseases, the molecular mechanism that regulates the
degradation of synaptophysin remains unsolved. Using
the cytoplasmic C terminus of synaptophysin as bait in a
yeast two-hybrid screen, we identified two synaptophy-
sin-binding proteins, Siah-1A and Siah-2, which are rat
homologues of Drosophila Seven in Absentia. We demon-
strated that Siah-1A and Siah-2 associate with synapto-
physin both in vitro and in vivo and defined the binding
domains of synaptophysin and Siah that mediate their
association. Siah proteins exist in both cytosolic and
membrane-associated pools and co-localize with synap-
tophysin on synaptic vesicles and early endosomes. In
addition, Siah proteins interact specifically with the
brain-enriched E2 ubiquitin-conjugating enzyme UbcH8
and facilitate the ubiquitination of synaptophysin. Fur-
thermore, overexpression of Siah proteins promotes the
degradation of synaptophysin via the ubiquitin-protea-
some pathway. Our findings indicate that Siah proteins
function as E3 ubiquitin-protein ligases to regulate the
ubiquitination and degradation of synaptophysin.
Synaptophysin is an abundant integral membrane protein of
synaptic vesicles with four transmembrane domains and a
unique cytoplasmic tail rich in proline, glycine, and tyrosine
(1–3). A number of studies have implicated a role for synapto-
physin in the regulation of neurotransmitter release and syn-
aptic plasticity (4–12). In addition, recent studies suggest that
synaptophysin also participates in the biogenesis and recycling
of synaptic vesicles, perhaps via interactions with cholesterol
and dynamin (13, 14). During development, synaptophysin ex-
pression occurs early in neurogenesis and is greatly up-regu-
lated during synaptogenesis (15–17). Increases in synaptophy-
sin expression have been found to correlate with long-term
potentiation, suggesting that the regulation of synaptophysin
expression may contribute to the mechanisms underlying
learning and memory (18, 19). Conversely, aberrant synapto-
physin expression has been associated with several neurode-
generative diseases and psychiatric disorders, such as Alzhei-
mer’s disease and schizophrenia (20–24). In some cases, an
alteration in the protein level of synaptophysin is observed
without a concomitant change at the mRNA level (22), implying
that impaired post-translational regulation may contribute to
abnormal synaptophysin expression.
Although ample evidence has implicated a role for synapto-
physin in neurotransmitter release, and altered synaptophysin
expression has been linked to malfunctions of the nervous
system, little is known about the mechanisms that regulate
synaptophysin expression, particularly at the post-transla-
tional level. To identify proteins that regulate synaptophysin
expression and/or function, we preformed a yeast two-hybrid
screen in rat brain for proteins that interact with synaptophy-
sin. The cytoplasmic tail of synaptophysin was used as bait,
because its unique amino acid composition and structure sug-
gests a possible role in protein-protein interaction (1). From
this screen, we isolated two synaptophysin-binding proteins,
Siah-1A and Siah-2, which are rat homologues of Drosophila
Seven in Absentia (Sina).1
Sina was originally discovered as a RING finger-containing
protein that is critically involved in the neuronal development
of the R7 photoreceptor cell in Drosophila (25). Sina functions
downstream of the tyrosine kinase receptor Sevenless and Ras/
Raf mitogen-activated protein kinase pathway (26–28). Recent
evidence indicates that Sina, together with phyllopod, pro-
motes the ubiquitin/proteasome-dependent degradation of
tramtrack, a negative regulator of neuronal differentiation (29,
30). In mammals, there are three highly conserved Sina homo-
logues, Siah-1A, Siah-1B, and Siah-2, which are abundantly
expressed in the brain as well as other tissues (31–34). Siah
proteins have been reported to interact with two neuronal
membrane proteins, DCC (deleted in colorectal cancer) and
group 1-metabotropic glutamate receptors (35, 36). Although it
remains to be determined if Siahs regulate the degradation of
metabotropic glutamate receptors, Siahs have been shown to
regulate the degradation of DCC via the ubiquitin-proteasome
pathway (35). Deletion analysis reveals that the RING finger
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containing the N-terminal domain of Siah is required for pro-
teolysis whereas the C terminus is involved in binding DCC
(37). Together, these studies suggest that Siah proteins may
act to regulate neuronal development and function by mediat-
ing the ubiquitin-dependent degradation of a number of neu-
ronal target proteins.
In the current study, we have found that Siah proteins reg-
ulate the ubiquitination and degradation of synaptophysin by
the proteasome pathway. Thus, Siah proteins may play an
important role in the turnover of synaptic vesicle proteins as
well as in neurodegenerative diseases where synaptophysin
expression is altered.
EXPERIMENTAL PROCEDURES
Yeast Two-hybrid Screen and cDNA Cloning—The bait plasmid,
pPC97-SYPtail, was constructed by subcloning the cytoplasmic C-ter-
minal tail (amino acids 218–307) of rat synaptophysin (38) into the
pPC97 vector (39, 40). For the two-hybrid screen, the yeast strain
CG-1945 (CLONTECH) was transformed sequentially with pPC97-
SYPtail and a rat hippocampal/cortical two-hybrid cDNA library (40),
using the lithium acetate method (41). Positive clones were selected on
3-aminotriazole (5 mM, Sigma Chemical Co.)-containing medium lack-
ing leucine, tryptophan, and histidine and verified with a filter assay for
-galactosidase activity. Prey plasmids were then recovered and re-
transformed into yeast with pPC97-SYPtail or controls to confirm the
specificity of the interaction. The N-terminal sequences of rat Siah-1A
and Siah-2 were cloned from rat brain Marathon-Ready cDNA using
5-RACE (rapid amplification of cDNA ends, CLONTECH). All cDNAs
were then sequenced multiple times on both strands, using an Applied
Biosystems 373A DNA sequencer.
Production of Recombinant Proteins—The full-length rat Siah-1A,
Siah-1A (C1), Siah-2 (C2), and Siah-2 deletion series (Siah-2 1 through
Siah-2 5) were subcloned into a pGEX-5X-2 vector (Amersham Bio-
sciences, Inc.) to obtain GST fusion proteins. Synaptophysin tail (amino
acids 218–307) and synaptophysin tail deletion series (Syp 1 through
Syp 5) were subcloned into the expression vector pET32c (Novagen) to
obtain S-tag synaptophysin fusion proteins. Fusion proteins were ex-
pressed in bacteria and purified as described previously (41).
In Vitro Binding Assays—GST fusion proteins or GST control were
immobilized on glutathione-agarose beads (Sigma) and incubated with
rat brain homogenates or purified S-tag proteins for 2 h at 4 °C in 50
mM NaH2PO4 (pH 7.2) and 0.05% Triton X-100, as previously described
(41). The incubation mixtures were then pelleted and extensively
washed with 50 mM NaH2PO4 (pH 7.2), 150 mM NaCl, and 0.05% Triton
X-100. Bound proteins were eluted by boiling in 2 Laemmli sample
buffer and analyzed by SDS-PAGE and immunoblotting with appropri-
ate antibodies.
Expression Constructs and Transfections—Conventional molecular
biological techniques were used to generate the following expression
constructs: pcDNA3-synaptophysin and pcDNA3-myc-synaptophysin,
which direct the expression of untagged and N-terminally myc-tagged
full-length synaptophysin, respectively; pCHA-Siah-1A, which directs
the expression of N-terminally HA-tagged full-length Siah-1A; pEGFP-
Siah-1A and pEGFP-Siah-2-2, which direct the expression of N-termi-
nally GFP-tagged, full-length Siah-1A, and truncated Siah-2 (amino
acids 224–325), respectively. Cells were transfected using Lipo-
fectAMINE (Invitrogen) as described by the manufacturer. In experi-
ments where the transient expression levels of synaptophysin were
compared in the presence and absence of HA-Siah-1A, a luciferase
reporter, pRSVL, was co-transfected as an internal control for transfec-
tion efficiency (41).
Antibodies—An anti-Siah antibody was raised in chicken against the
synthetic peptide CLTLHHTEKPEHEDI, corresponding to amino acids
147–160 of rat Siah-2. The N-terminal cysteine residue was added for
the coupling purposes. The antibody was affinity-purified using the
immunogen peptide coupled to a SulfoLink column (Pierce). Other
antibodies used in this study include the following: anti-synaptophysin
(SVP-38, Sigma), anti-HA (3F10, Roche Molecular Biochemicals;
HA.11, Covance), anti-myc (9E10.3, Neomarkers), anti-EEA1 (Trans-
duction Laboratories), anti-actin (C4, Roche Molecular Biochemicals);
and secondary antibodies coupled with horseradish peroxidase, fluores-
cein, or Texas Red (Jackson ImmunoResearch Laboratories, Inc.).
Immunoprecipitations—Extracts were prepared from HeLa or CHO
cells transiently transfected with indicated plasmids, and immunopre-
cipitation were preformed as described previously (42), using anti-HA
antibody (3F10), anti-myc (9E10.3), anti-synaptophysin antibody (SVP-
38), or control IgG. The immunocomplexes were recovered by incuba-
tion with protein G- or protein A-Sepharose beads (Sigma). After ex-
tensive washes, the immunocomplexes were dissociated by boiling in
the Laemmli sample buffer, and analyzed by SDS-PAGE and
immunoblotting.
Immunofluorescence Microscopy—PC12 cells were grown on poly-
L-lysine-coated glass coverslips and differentiated with nerve growth
factor (NGF, 100 ng/ml) for 48 h. CHO cells were transfected with
pEGFP-Siah-1A alone or in combination with pcDNA3-synapto-
physin. Cells were fixed for 10 min in 3.4% paraformaldehyde in 1
PBS and permeabilized for 30 min in 1 PBS plus 1% bovine serum
albumin and 0.1% saponin prior to incubation with antibodies. The
primary antibodies to synaptophysin, Siah or EEA1, were applied in
1 PBS plus 1% bovine serum albumin and 0.1% saponin for 1 h.
Cells were incubated for 1 h with secondary antibodies conjugated to
Texas Red. Coverslips were mounted in the Vectashield mounting
medium (Vector Laboratories, Inc.) and then analyzed using a Leica
TCS-NT confocal microscope with fluorescein isothiocyanate and
Texas Red filters. The images were then processed using Adobe
Photoshop 5.0 (Adobe Systems, Inc.).
Membrane Association Analyses—Separation of HA-Siah-1A-trans-
fected CHO cells into cytosol fraction (50,000  g supernatant) and
membrane fraction (50,000  g pellet) were preformed as previously
described (41). The membrane fractions were subjected to extraction
studies as described (41), using 0.1 M NaHCO3 or 4 M urea.
Proteolysis Inhibitor Treatment of Cells—PC12 cells or HeLa cells
expressing Siah-1A and synaptophysin were incubated for 8 h at 37 °C
with the proteasome inhibitor MG132 (20 M, Calbiochem), the cysteine
protease inhibitor E64 (50 M, Sigma), or vehicle (Me2SO, final concen-
tration 0.1%). Cells were then lysed, and the protein concentrations of
the lysates were determined by BCA protein assay (Pierce). An equal
amount of protein from each lysate was then analyzed by SDS-PAGE
and immunoblotting.
[35S]Methionine Pulse-chase Experiments—HeLa cells were co-trans-
fected with pcDNA3-synaptophysin and either pCHA vector or pCHA-
Siah-1A. Forty-eight hours later, the cells were washed and incubated
for 30 min with Met/Cys-free DMEM. The medium was then replaced
with Met/Cys-free DMEM containing 200 Ci of [35S]Met/Cys (1000
Ci/mmol) express protein labeling mix (PerkinElmer Life Sciences).
After incubation for 1 h, the radioactive medium was removed by
extensive washes with non-radioactive DMEM. Cells were then incu-
bated for chase intervals of 0, 2, 4, 6, 8, 12, 24, and 48 h in non-
radioactive DMEM supplemented with 10% fetal bovine serum and 5
the normal concentration of methionine and cysteine. Cells were lysed
after appropriate chase time. An equal amount of protein from each
lysate was immunoprecipitated using anti-synaptophysin antibody
(SVP-38). Immunoprecipitates were analyzed by SDS-PAGE and auto-
radiography. The level of synaptophysin was quantified with a Phos-
phorImager (Molecular Dynamics).
Ubiquitination Assays—CHO cells were transfected with combina-
tions of the following plasmids: pcDNA3-myc3-synaptophysin, pEGFP-
Siah-1A, pEGFP-Siah-1A N, and pCHA-ubiquitin (43). Twenty-four
hours after transfection, the cells were incubated for 8 h with 20 M
MG132 (Calbiochem). The cells were then lysed, and an equal amount
of protein from each lysate was immunoprecipitated using an anti-myc
antibody (9E10.3). Immunoprecipitates were analyzed by SDS-PAGE
and immunoblotting with an anti-HA antibody to detect synaptophysin-
polyubiquitin conjugates.
RESULTS
Identification of Rat Siah-1A and Siah-2 as Synaptophysin-
interacting Proteins—To identify proteins that interact with
synaptophysin, we used the yeast two-hybrid system to screen
a rat hippocampal/cortical cDNA library with the C-terminal
89 amino acids of synaptophysin as bait. Positive clones were
rescued and confirmed by retransformation experiments dem-
onstrating that these clones only interact with synaptophysin,
but not with unrelated proteins such as SNAP-25 (data not
shown). Out of 6.6  106 yeast transformants screened, we
isolated 35 positive clones, of which three clones encode rat
Siah-1A, whereas 32 clones encode rat Siah-2 (Fig. 1A). Previ-
ously, three murine Siah proteins, Siah-1A, Siah-1B, and
Siah-2, have been described (31). However, only two human
homologues, Siah-1A and Siah-2, have been identified, which
share 78% amino acid identity with each other (31, 33, 34).
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Despite efforts by several different groups, no human cDNAs
corresponding to murine Siah-1B could be detected (32, 33).
Similarly, we could not detect rat cDNAs corresponding to
murine Siah-1B by 5-RACE and hybridization studies in the
two-hybrid library and other rat cDNA libraries nor in the
mRNA preparations. Together, these results suggest that
Siah-1B may be a mouse-specific splice variant that does not
exist in other species. The facts that Siah-1A and Siah-2 are the
only positive synaptophysin-interacting clones and that they
were isolated multiple times from the yeast two-hybrid screen
FIG. 1. Isolation of rat Siah-1A and Siah-2 as synaptophysin-interacting proteins from a yeast two-hybrid screen. A, domain
structures of Siah-1A and Siah-2. The following domains are indicated: RING, RING finger motif (Siah-1A, 41–74; Siah-2, 80–114); C/H-rich,
cysteine/histidine-rich region (Siah-1A, 98–152; Siah-2, 138–192). The conserved region between Siah-1A and Siah-2 is marked. The locations of
the synaptophysin-interacting Siah clones isolated from the yeast two-hybrid screen are indicated below the domain structures. The number of
times that each clone was independently isolated is indicated on the right. B, amino acid sequence alignment of the rat Siah proteins with the
human and Drosophila homologues. Asterisks indicate the conserved cysteine and histidine residues in the RING finger motif, whereas the solid
squares indicate the cysteine and histidine residues in the C/H-rich region.
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suggest that the detected interaction between Siah proteins
and synaptophysin may be physiologically relevant.
Sina was originally identified as a protein that is required for
R7 photoreceptor development in Drosophila (25). Data bank
searches reveal the presence of Sina homologues in a number of
organisms, including human, mouse, Caenorhabditis elegans,
Xenopus, and Arabidopsis. The amino acid sequences of Sina/
Siah proteins are extremely well conserved (31, 33, 34). For
example, rat Siah proteins share 99 and 75% amino acid
identity with human Siah proteins and Drosophila Sina, re-
spectively (Fig. 1B). Sina/Siah proteins all contain an N-termi-
nal RING finger motif (C3HC4) followed by a conserved cys-
teine/histidine-rich region (C2HC3H2), which may represent a
novel class of Zn2-binding motifs (Fig. 1). RING finger motifs
are cysteine/histidine-rich, Zn2-binding domains that are
thought to mediate protein-protein interactions (44, 45). Recent
studies indicate that RING finger motifs may function in ubiq-
uitination as ubiquitin ligases via interaction with ubiquitin-
conjugating enzymes (46, 47). Deletion analysis reveals that,
although the N-terminal RING finger motif is required for
proteolysis function, the C-terminal region of Siah proteins
may be involved in the interaction with target proteins (37).
Interestingly, the positive synaptophysin-interacting clones,
C1, C2, and C3, all contain the C-terminal region of Siah
proteins (Fig. 1A), further supporting the notion that the C-
terminal region of Siah is the target protein-binding domain.
Siah-1A and Siah-2 Interact with Synaptophysin in Vitro
and in Vivo—To determine if the synaptophysin-Siah interac-
tion detected in the yeast two-hybrid system actually occurs in
vitro, GST-Siah fusion proteins immobilized on glutathione
beads were used to affinity-purify (“pull-down”) endogenous
synaptophysin from rat brain homogenate. As shown in Fig.
2A, GST fusion proteins, containing either full-length Siah-1A
or N-terminally truncated forms of Siah-1A and Siah-2, were
able to bind endogenous synaptophysin. In contrast, control
GST proteins were unable to bind synaptophysin, confirming
the specificity of the binding. To further determine if synapto-
physin associates with Siah proteins in vivo, co-immunopre-
cipitation experiments were performed using lysates of CHO
cells co-transfected with synaptophysin and HA-tagged
Siah-1A or Siah-2. As shown in Fig. 2B, synaptophysin and
HA-Siah-1A were co-immunoprecipitated by the anti-HA anti-
body but not by the IgG control. Similarly, synaptophysin and
HA-Siah-2 (C2) were also co-immunoprecipitated (Fig. 2C).
These results confirm the specific association of synaptophysin
with Siah proteins in mammalian cells.
Identification of Domains Involved in the Siah-Synaptophy-
sin Association—As shown in Fig. 1, Siah-1A and Siah-2 are
highly homologous proteins that share a conserved region with
90% amino acid identity (31, 33). The three Siah clones isolated
from the yeast two-hybrid screen encode either part or com-
plete sequences of the conserved region (Fig. 1A). To further
define the specific domain of Siah proteins responsible for the
interaction with synaptophysin, we generated a series of GST
fusion proteins containing various truncations of the Siah-2-
conserved region and analyzed their interaction with endoge-
nous synaptophysin from brain extracts (Fig. 3A). Deletion of
the RING finger and the cysteine/histidine-rich motif (Siah-2
1 and Siah-2 2) of Siah-2 had no effect on its interaction with
synaptophysin, indicating that these regions are not involved
in binding synaptophysin. Similarly, the C-terminal residues
278–325 (Siah-2 3) are dispensable for association with syn-
aptophysin. However, further deletion of amino acids 225–278
(Siah-2 4) abolished the ability of Siah to interact with syn-
aptophysin, indicating that this region is necessary for binding
synaptophysin. Conversely, GST fusion protein containing
amino acids 225–278 (Siah-2 5) is capable of binding synap-
tophysin (Fig. 3A). These data indicate that the region between
residues 225 and 278 is necessary and sufficient for binding
synaptophysin.
To further understand the structural requirements underly-
ing the Siah-synaptophysin interaction, we preformed similar
deletion analysis of the cytoplasmic tail of synaptophysin to
map the Siah-binding site. A series of S-tag synaptophysin
deletion mutants were generated and tested for their ability to
bind GST-Siah-1A fusion proteins in binding assays in vitro
(Fig. 3B). The cytoplasmic tail of synaptophysin contains nine
copies of an imperfect pentapeptide repeat, YGP(Q)QG, with
unknown function (1, 3). Only the recombinant synaptophysin
proteins containing the C-terminal three repeats (Syp 4 and
Syp 5) are capable of binding Siah-1A. In contrast, the syn-
aptophysin recombinant proteins containing the other repeats
(Syp 1 to Syp 3) were unable to bind Siah.
Siah Exists in Both Cytosolic and Membrane-associated
Pools and Colocalizes with Synaptophysin in Transfected CHO
Cells—To investigate the intracellular distribution of Siah pro-
teins, we first performed subcellular fractionation experiments
to separate the postnuclear supernatant from HA-tagged Siah-
1A-transfected CHO cells into cytosol and membrane fractions.
Western blot analysis of these fractions revealed that Siah-1A
was present in both the cytosol and membrane fraction, al-
though the relative amount of Siah-1A in the membrane frac-
tion was severalfold more than that in the cytosol fraction (Fig.
4E). To examine the nature of Siah-1A association with mem-
branes, the membrane fraction was extracted with 0.1 M
FIG. 2. In vitro and in vivo interaction between synaptophysin
and Siah proteins. A, GST-Siah fusion proteins were immobilized on
glutathione-Sepharose beads and incubated with rat brain homogenate
(Input). After extensive washes, bound proteins were eluted and ana-
lyzed by SDS-PAGE and immunoblotting using a monoclonal antibody
against synaptophysin (upper panel). GST-Siah fusion proteins were
shown as Ponceau S staining (lower panel). B, co-immunoprecipitation
of synaptophysin with Siah-1A from CHO cells. Extracts from CHO
cells co-transfected with pcDNA3-synaptophysin and pCHA-Siah-1A
were subjected to immunoprecipitation with anti-HA antibody (3F10) or
control rat IgG. The immunoprecipitates were analyzed by immunoblot-
ting for synaptophysin (Syp) and HA-Siah-1A. C, co-immunoprecipita-
tion of synaptophysin with Siah-2 from CHO cells. Extracts from cells
co-transfected with pcDNA3-synaptophysin and pCHA-Siah-2 (C2)
were immunoprecipitated as described in B. The immunoprecipitates
were analyzed by immunoblotting for synaptophysin (Syp) and
HA-Siah-2.
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NaHCO3 at pH 11.5 or 4 M urea (Fig. 4E). Unlike SNAP-23 (a
protein bound to membranes via covalently linked palmitic
acids), which was resistant to extraction by high pH and urea,
a significant percentage of the Siah-1A protein was extracted
by these treatments, suggesting that Siah-1A is peripherally
associated with membranes via hydrophilic interactions. It is
worthy of note that the extraction of Siah-1A seems to be
incomplete, because a significant portion of the Siah-1A protein
was detected in the pellet after various treatments. Similar
incomplete extraction has been observed for many peripherally
associated membrane proteins, such as synapsin I, parkin, and
rsec8 (48–50). The Siah protein in the pellet might represent
the denatured protein that has pelleted as an insoluble aggre-
gate and/or the Siah protein trapped inside the membrane
vesicles during the subcellular fractionation procedure.
We then use immunofluorescence confocal microscopy to ex-
amine the subcellular localization of N-terminally HA- or GFP-
tagged full-length Siah-1A expressed in CHO cells. Both HA-
and GFP-tagged Siah-1A exhibited a similar punctate staining
pattern (Fig. 4, A and C; data not shown), which is consistent
with that observed for FLAG- and myc-tagged Sina and Siah-1
proteins expressed in Drosophila and mammalian cells (33, 35,
37, 51). The punctate staining pattern suggests that Siah pro-
teins are present on vesicular structures, although the identity
of such structures has not yet been characterized. Simultane-
ous staining of cells co-expressing synaptophysin and GFP-
Siah-1A with anti-synaptophysin antibody revealed a signifi-
cant overlap in the distribution of these two proteins (Fig. 4, A
and B), providing additional evidence for their association in
vivo. Previous studies have shown that, when expressed in
non-neuronal cells such as CHO cells, synaptophysin is tar-
geted to early endosomes (52–56). The co-localization of Siah
FIG. 3. Biochemical characterization of the association between synaptophysin and Siah proteins. A, mapping of the synaptophysin-
binding domain of Siah-1A. Schematic representation of Siah proteins and deletion mutants encoded by GST fusion cDNA constructs is shown on
the left. These fusion proteins were immobilized on glutathione-Sepharose beads (lower panel, Ponceau S staining) and incubated with rat brain
homogenate (Input). After extensive washes, bound proteins were analyzed by SDS-PAGE and immunoblotting for synaptophysin (upper panel).
B, identification of the Siah-binding domain of synaptophysin. Schematic representation of the C-terminal region of synaptophysin and its deletion
mutants is shown on the left. Numbers indicate the pentapeptide repeats. These deletion mutants were expressed as S-tag fusion proteins (upper
panel) and incubated with immobilized GST-Siah-1A. Bound proteins were analyzed by immunoblotting with the horseradish peroxidase-
conjugated S-protein that specifically binds the S-tag (middle panel). Equal loading of GST-Siah-1A was verified by Ponceau S staining (lower
panel). Syp, synaptophysin.
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proteins with synaptophysin suggests that Siah proteins may
be localized to early endosomes. To examine this possibility, we
compared the distribution of Siah-1A with early endosome
antigen 1 (EEA1). EEA1, a core component of early endosome
docking and fusion machinery, is one of the most specific mark-
ers for early endosomes known to date (57, 58). The distribution
of Siah-1A significantly overlaps with that of EEA1 (Fig. 4, C
and D), suggesting that at least a fraction of Siah proteins are
associated with early endosomes in transfected CHO cells.
Colocalization of Endogenous Siah Proteins with Synapto-
physin on Synaptic-like Microvesicles and Early Endosomes in
PC12 Cells—Because synaptophysin is specifically expressed
in neurons and neuroendocrine cells, it would be of particular
interest to determine if endogenous Siah proteins co-localize
with synaptophysin in these cells. For characterization of en-
dogenous Siah proteins, a chicken anti-Siah antibody was gen-
erated against a 14-amino acid peptide sequence of rat Siah-2,
and affinity-purified using the immunogen peptide column.
The affinity-purified anti-Siah antibody was used in immuno-
fluorescence studies of endogenous Siah protein localization in
rat pheochromocytoma PC12 cells. PC12 is a well characterized
neuroendocrine cell line that shares many characteristics of
sympathetic neurons, such as secretion of neurotransmitters
and the response to nerve growth factor (NGF) (59). For immu-
nofluorescence studies, PC12 cells were treated with NGF to
induce the formation of neurites, which are enriched in synap-
tic-like microvesicles but not endosomes (60). Immunostaining
of NGF-differentiated PC12 cells using the affinity-purified
anti-Siah antibody revealed a punctate staining pattern, which
demonstrates that Siah proteins are localized on vesicular
structures in the cell body and neuritic processes (Fig. 5, A and
D). No staining was observed when the pre-immune chicken
IgY fraction was used or the anti-Siah antibody was omitted
(data not shown), confirming that the Siah staining is specific.
To determine whether endogenous Siah proteins co-localize
with synaptophysin, we performed double-immunofluorescence
experiments to compare the distribution of Siah proteins with
synaptophysin in NGF-differentiated PC12 cells (Fig. 5, A–C).
The results revealed a substantial overlap between Siah and
synaptophysin immunoreactivity, particularly in the neuritic
processes, including the tip of neurites. It is well established
that synaptophysin is localized to synaptic-like microvesicles
and early endosomes in PC12 cells (52, 54–56, 61). Moreover,
previous studies have shown that early endosomes, as detected
by transferrin receptor immunoreactivity or internalized trans-
ferrin staining, are restricted to the cell body and are virtually
absent from neurites in PC12 cells (52, 60). Thus, the overlap-
ping distribution of Siah and synaptophysin in neurites indi-
cates that a significant portion of Siah proteins is localized on
synaptic-like microvesicles.
Because a fraction of synaptophysin is localized to early
endosomes in PC12 cells and our studies revealed an early
endosomal localization of Siah proteins in transfected CHO
cells (Fig. 4, C and D), we sought to determine if endogenous
Siah proteins are also localized to early endosomes in PC12
cells. Consistent with previous studies (52, 60), EEA1 immu-
nostaining is concentrated in the cell body and virtually unde-
tectable in neurites of NGF-differentiated PC12 cells (Fig. 5E).
Simultaneous staining of the same cells with anti-Siah and
anti-EEA1 antibodies revealed that the distribution of Siah
proteins overlapped significantly with that of EEA1 (Fig. 5,
D–F), indicating that a fraction of endogenous Siah proteins is
associated with early endosomes.
Regulation of Synaptophysin Stability by Siah Proteins—
Because Siah proteins have been shown to regulate the degra-
dation of several interacting proteins, we assessed the effect of
Siah overexpression on the expression and stability of synap-
tophysin. HeLa cells were co-transfected with pcDNA3-synap-
tophysin and either pCHA-Siah-1A or pCHA vector control,
and the protein expression level of synaptophysin was meas-
ured by Western blot analysis. The results demonstrate that
overexpression of Siah-1A leads to a significant decrease in the
steady-state level of synaptophysin expression (Fig. 7A). The
FIG. 4. Characterization of subcellular distribution of Siah
proteins in transfected CHO cells. A–D, co-localization of Siah-1A
with synaptophysin and EEA1 in transfected CHO cells. CHO cells
were transiently transfected with pEGFP-Siah-1A either alone (C and
D) or in combination with pcDNA3-synaptophysin (A and B). The dis-
tribution of GFP-Siah-1A was directly visualized by the green fluores-
cence emitted by GFP (A and C). The same cells were stained with
primary antibodies against synaptophysin (B) or endogenous EEA1 (D),
followed by detection with secondary antibodies conjugated to Texas
Red. The arrows indicate vesicular structures clearly visible in both
panels (colocalized), whereas the arrowheads mark the vesicular struc-
tures unique to each panel (not co-localized). Scale bar  10 m. E,
Siah-1A exists in both cytosolic and membrane-bound pools. Post-
nuclear supernatant (T) from HA-Siah-1A-transfected CHO cells was
separated in cytosol (C) and membrane (M) fractions. The membranes
were extracted with 0.1 M NaHCO3 or 4 M urea, and then separated into
soluble (S) and pellet (P) fractions. Aliquots representing an equal
percentage of each fraction were analyzed by SDS-PAGE and immuno-
blotting for HA-Siah-1A and SNAP-23.
FIG. 5. Comparison of the distribution of Siah proteins with
synaptophysin and EEA1 in NGF-differentiated PC12 cells.
NGF-differentiated PC12 cells were stained with a chicken anti-Siah
antibody, which was detected with a secondary antibody conjugated to
fluorescein (A and D). The same cells were simultaneously stained with
primary antibodies against synaptophysin (B), or EEA1 (E), which were
detected with secondary antibodies conjugated to Texas Red. Superim-
posed images (C and F) demonstrate the overlapping distribution of
these proteins. Scale bar  10 m.
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decrease in synaptophysin level is not due to a difference in the
transfection efficiency, because similar results were obtained
when the transfection efficiency was normalized using a co-
transfected luciferase reporter gene (data not shown).
To further determine whether Siah proteins regulate the
degradation of synaptophysin, we examined the effect of over-
expression of Siah-1A on synaptophysin protein turnover by
pulse-chase experiments (Fig. 6). In cells co-transfected with
synaptophysin and control vector, the half-life of synaptophy-
sin was 6 h (Fig. 6), which is consistent with the half-life of
endogenous synaptophysin in cultured hippocampal neurons
(62). In contrast, when synaptophysin was co-expressed with
Siah-1A, the half-life of synaptophysin protein was reduced to
1.8 h (Fig. 6). Taken together, these results indicate that Siah
proteins have the ability to regulate synaptophysin turnover.
Siah Regulates Synaptophysin Degradation via the Ubiq-
uitin-proteasome Pathway—Next, we sought to determine
whether the enhanced degradation of synaptophysin by Siah
proteins is mediated by the proteasome pathway. HeLa cells
that have been co-transfected with synaptophysin and Siah-1A
were treated for 8 h with various inhibitors of proteolytic path-
ways, and the synaptophysin levels were then analyzed by
Western blotting. As shown in Fig. 7A, the enhanced degrada-
tion of synaptophysin by Siah-1A overexpression is blocked by
MG132, a potent inhibitor of proteasome function (63). A sim-
ilar effect was also observed when cells were treated with
lactacystin, an irreversible inhibitor of the proteasome path-
way (data not shown) (63). In contrast, E64, an inhibitor of
lysosomal cysteine proteases, had no effect.
Because proteasome-dependent proteolysis involves the
ubiquitination of target proteins, we investigated whether
Siah-1A accelerates the degradation of synaptophysin by pro-
moting the ubiquitination of synaptophysin. Myc-tagged syn-
aptophysin was co-expressed in CHO cells along with HA-
tagged ubiquitin in the absence or presence of exogenous
Siah-1A or an N-terminally truncated Siah-1A (Siah-1A N,
amino acids 137–282). Cell lysates were subjected to immuno-
precipitation with an anti-myc antibody followed by immuno-
blotting with an anti-HA antibody to detect ubiquitin-conju-
gated synaptophysin (Fig. 7B). In the absence of exogenous
Siah proteins, synaptophysin was ubiquitinated, because the
immunoprecipitate contained high molecular weight smears
detected by the anti-HA antibody immunoblotting. Overexpres-
sion of Siah-1A enhanced the ubiquitination of synaptophysin,
because increased levels of HA-tagged ubiquitin were detected
on synaptophysin. Conversely, overexpression of Siah-1A N, a
dominant negative form of Siah-1A that lacks the RING finger-
containing N-terminal region, blocked the ubiquitination of
synaptophysin. Taken together, these data indicate that Siah
proteins target synaptophysin for ubiquitin-mediated degrada-
tion via the 26 S proteasome.
Siah Associates with the E2 Ubiquitin-conjugating Enzyme
UbcH8 and Regulates the Degradation of Endogenous Synap-
tophysin in PC12 Cells—To address the question whether Siah
proteins could regulate the degradation of endogenous synap-
tophysin, we examined the effect of overexpression of myc-
Siah-2 on the protein level of endogenous synaptophysin in
PC12 cells. Cell lysates were prepared from PC12 cells trans-
fected with pcDNA3-myc-Siah-2 (35) or a pcDNA3-myc vector
FIG. 6. Siah regulates the stability of synaptophysin protein.
A, determination of synaptophysin half-life in the presence or absence
of Siah-1A. HeLa cells were co-transfected with pcDNA3-synaptophysin
and either pCHA vector or pCHA-Siah-1A. Forty-eight hours after
transfection, the cells were pulse-labeled for 1 h with DMEM containing
[35S]Met/Cys, chased with non-radioactive Met/Cys for the indicated
time, and then lysed. Cell lysates were subjected to immunoprecipita-
tion with monoclonal anti-synaptophysin antibody, and immunoprecipi-
tates were analyzed by SDS-PAGE and autoradiography. B, the level of
synaptophysin was measured by quantification of the intensity of the
38-kDa synaptophysin protein using a PhosphorImager, expressed as a
percentage of the synaptophysin level at the 0 h, and plotted as a
function of chase time.
FIG. 7. Siah targets synaptophysin for degradation by the
ubiquitin-proteasome pathway. A, effect of Siah-1A on synaptophy-
sin degradation is blocked by proteasome inhibitors. HeLa cells were
co-transfected with pcDNA3-synaptophysin and either pCHA-Siah-1A
or pCHA vector. Twenty-four hours later, cells were incubated for 8 h at
37 °C with Me2SO, proteasome inhibitor MG132 (20 M in Me2SO), or
cysteine protease inhibitor E64 (50 M). Cells were then lysed, and an
equal amount of protein from each lysate was analyzed by immunoblot-
ting for synaptophysin and actin. B, Siah-1A promotes ubiquitination of
synaptophysin. Twenty-four hours after CHO cells were transfected
with indicated plasmids, cells were treated for 6 h with MG132 (20 M).
Myc-tagged synaptophysin proteins were then immunoprecipitated
from cell lysates with an anti-myc antibody. The immunoprecipitates
were analyzed by immunoblotting with an anti-HA antibody to identify
synaptophysin proteins to which the HA-ubiquitin polypeptide had
been attached. The blot was then stripped and reprobed with an anti-
synaptophysin antibody. Syp, synaptophysin.
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control, and the steady-state levels of myc-Siah-2 and synap-
tophysin in these lysates were determined by Western blot
analysis (Fig. 8A). Consistent with previous reports (35, 37),
myc-tagged Siah-2 was found to be expressed at a relatively low
level in transfected PC12 cells, perhaps as a result of self-
regulating its own stability (see “Discussion”). Comparison
with the control transfection reveals that the expression of
exogenous Siah-2 significantly down-regulated the protein
level of endogenous synaptophysin. To further determine
whether the down-regulation effect of Siah-2 overexpression is
mediated via the ubiquitin-proteasome degradation pathway,
PC12 cells expressing myc-Siah-2 were treated with various
inhibitors of protein degradation. Comparison of the synapto-
physin levels in treated versus untreated cells shows that the
down-regulation effect of Siah-2 overexpression is blocked by
the proteasome inhibitor MG132 but not by the lysosomal
protease inhibitor E64 (Fig. 8A). These results suggest that
Siah proteins regulate the degradation of endogenous synapto-
physin in PC12 cells via the ubiquitin-proteasome pathway. As
previously reported for Siah-1 (35, 37), the expression levels of
myc-Siah-2 were increased upon inhibition of the proteasome
activity by MG132 (Fig. 8A), suggesting that the stability of
Siah-2 itself is controlled by the proteasome pathway. Interest-
ingly, Siah has recently been shown to promote its own ubiq-
uitination (64), and this autoubiquitination of Siah could lead
to the self-regulation of its own degradation.
A likely mechanism by which Siah regulates the ubiquitina-
tion and degradation of synaptophysin is that Siah may serve
as an E3 ubiquitin-protein ligase for synaptophysin. E3 ligases
determine the specificity of protein degradation by recognizing
a unique set of substrates and cooperating with a specific E2
ubiquitin-conjugating enzyme to catalyze the ubiquitination
(65). Although Sina has been shown to interact with the E2
enzyme UbcD1 in Drosophila (30), the one or more cognate E2
ubiquitin-conjugating enzymes for mammalian Siah proteins
remain to be clarified. To test whether Siah interacts with a
specific E2 enzyme, we expressed various HA-tagged E2 en-
zymes (66) by transient transfection into HeLa cells along with
myc-tagged Siah-2. The interaction of these E2 enzymes with
Siah-2 was examined by immunoprecipitation with an anti-
myc antibody followed by immunoblotting with an anti-HA
antibody (Fig. 8B). The results reveal that Siah-2 specifically
interacts with UbcH8, an E2 enzyme that is abundantly ex-
pressed in the central nervous system (67) but not with other
E2 enzymes examined, namely UbcH5 and UbcH7. These data
suggest that Siah may function as E3 ubiquitin ligase to reg-
ulate the ubiquitination and degradation of synaptophysin in
conjunction with the brain-enriched E2 ubiquitin-conjugating
enzyme UbcH8.
DISCUSSION
Although synaptophysin has been implicated in neurotrans-
mitter release, and decreased synaptophysin levels have been
associated with several neurodegenerative diseases, the molec-
ular mechanism underlying the degradation and turnover of
synaptophysin remains unsolved. In the current study, we
demonstrate that Siah proteins interact with synaptophysin
and regulate the degradation of synaptophysin via the ubiq-
uitin-proteasome pathway. It has been previously shown that
Sina/Siah proteins promote ubiquitin-proteasome-dependent
degradation of several nuclear proteins (29, 30, 68) as well as
DCC, a neuronal plasma membrane protein (35). The evidence
presented here indicates that Siah proteins also regulate the
degradation of synaptophysin, a synaptic vesicle membrane
protein.
Sina/Siah proteins are widely expressed in the embryo and
adult tissues, and a high level of Siah-2 expression is found in
certain neuronal tissues, including olfactory epithelium, retina,
and forebrain (25, 31, 33, 69, 70). Our subcellular fractionation
studies have shown that Siah proteins exist in both cytosolic
and membrane-associated pools. Furthermore, immunofluores-
cence studies reveal that, in NGF-differentiated PC12 cells,
Siah proteins are primarily localized in the cell body and neu-
ritic processes, where they are associated with synaptic-like
microvesicles and early endosomes. This localization pattern
suggests that Siah proteins may play an important role in
regulation of the expression levels of synaptophysin and per-
haps other synaptic vesicle proteins at nerve terminals.
The ubiquitin-proteasome pathway consists of two major
steps: The conjugation of ubiquitin to the substrate and subse-
quent degradation of the ubiquitinated protein by the 26 S
proteasome (71). Ubiquitin conjugation involves sequential re-
actions in which ubiquitin is first activated by a ubiquitin-
activating enzyme (E1), then transferred to a ubiquitin-conju-
gating enzyme (Ubc or E2), and finally ligated to the substrate
by a ubiquitin-protein ligase (E3) (65, 71, 72). The specificity of
ubiquitin conjugation is conferred by the E3, which binds the
substrate protein and cooperates with the E2 enzyme to cata-
lyze the covalent attachment of ubiquitin to the substrate. Our
data support a model in which Siah regulates the degradation
of synaptophysin by acting as an E3 ubiquitin-protein ligase to
catalyze the ubiquitination of synaptophysin in conjunction
with the brain-enriched E2 ubiquitin-conjugating enzyme
UbcH8. Formation of a polyubiquitin chain then targets syn-
aptophysin for degradation by the 26 S proteasome.
The structural requirement underlying the recognition of
substrates by E3 ligases is largely unknown. An E3 can recog-
nize several substrates (73), which is clearly the case with Siah
FIG. 8. Siah binds selectively to UbcH8 and down-regulates endogenous synaptophysin in PC12 cells. A, Siah-2 promotes synapto-
physin degradation via the ubiquitin-proteasome pathway. PC12 cells were transfected with pcDNA3-myc-Siah-2 or the pcDNA3-myc vector.
Twenty-four hours later, cells were incubated for 8 h at 37 °C with Me2SO, proteasome inhibitor MG132 (20 M in Me2SO), or cysteine protease
inhibitor E64 (50 M). Cells were then lysed, and equal amounts of protein from each lysate were analyzed by immunoblotting for synaptophysin,
myc-Siah-2, and actin. B, Siah-2 interacts specifically with UbcH8. HeLa cells were co-transfected with pcDNA3-myc-Siah-2 and pRK5-HA-UbcH5,
pRK5-HA-UbcH7, or pRK5-HA-UbcH8. Cell lysates of transfected cells were subjected to immunoprecipitation with an anti-myc antibody. The
immunoprecipitates were then analyzed by immunoblotting with antibodies against HA, myc, or actin. Syp, synaptophysin.
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proteins. Previous studies have shown that, although the N-
terminal RING finger domain of Siah proteins is required for
interacting with E2s, the C-terminal region is involved in bind-
ing substrates such as DCC and N-CoR, although the exact
binding site has not been described (37). Our deletion results
indicate that the synaptophysin-binding site resides within the
region between residues 225 and 278 of Siah-2. This region
(225–278) of Siah-2 is included in the previously reported sub-
strate-binding regions (108–324 for N-CoR; 184–324 for DCC)
(35, 68). It will be interesting to determine whether the binding
site for these substrates also falls between residues 225 and
278 of Siah-2.
Synaptophysin has a unique C-terminal cytoplasmic tail that
contains nine copies of an imperfect pentapeptide repeat, YG-
P(Q)QG. The function of these repeats is not understood, al-
though they have been proposed to mediate protein-protein
interactions (1, 3). By using deletion analysis, we have shown
that the C terminus of synaptophysin containing the last three
repeats (residue 278–307) is responsible for binding Siah-1A.
The amino acid sequence (278–307) of synaptophysin C termi-
nus is well conserved evolutionarily, further supporting the
functional significance of this region. Moreover, this region is
also well conserved in synaptoporin, a 37-kDa protein with 58%
amino acid identity to synaptophysin (74, 75), suggesting that
synaptoporin could also be a substrate of Siah proteins. In
support of this hypothesis, our preliminary studies have shown
that synaptoporin physically interacts with Siah proteins.2
The ubiquitin-proteasome pathway plays a crucial role in the
degradation of proteins involved in a variety of cellular pro-
cesses, including differentiation, proliferation, and apoptosis
(65, 71, 76). However, the role of the ubiquitin-proteasome
pathway in the degradation of synaptic vesicle-associated pro-
teins remains poorly characterized, despite the identification of
ubiquitin in synaptic terminals (77, 78). In this study, we have
shown that synaptophysin, an integral membrane protein of
synaptic vesicles, is ubiquitinated and degraded by the protea-
some pathway. Furthermore, the ubiquitin-dependent degra-
dation of synaptophysin is regulated by Siah proteins, a family
of putative E3 ligases. Interestingly, Parkin, a protein impli-
cated in the pathogenesis of familial Parkinson’s disease, has
been shown to act as an E3 ligase for the degradation of
CDCrel-1, a member of the septin family that is associated with
synaptic vesicles (66). Moreover, Parkin has recently been re-
ported to be an E3 ligase for the degradation of -synuclein, a
synaptic vesicle-associated protein whose mutations have been
linked to familial Parkinson’s disease (79).
It is becoming increasingly clear that malfunctions of the
ubiquitin-proteasome pathway are critically involved in the
pathogenesis of a number of neurodegenerative diseases, such
as Parkinson’s disease, Alzheimer’s disease, and Huntington’s
disease (65, 80). Since altered synaptophysin expression levels
have been linked to several neurological disorders, dysregula-
tion of synaptophysin degradation by Siah proteins may repre-
sent a mechanism contributing to the pathophysiology of these
diseases. Interestingly, Siah proteins have been reported to be
up-regulated during apoptosis (34, 69, 81). Given that overex-
pression of Siah proteins promotes the degradation of synap-
tophysin as well as DCC, it is possible that increased Siah
expression promotes the degeneration of synaptic terminals
and the death of neurons via accelerated degradation of these
and other yet to be identified substrate proteins. Further stud-
ies of Siah proteins and their protein-protein interactions are
likely to yield novel insights into the mechanisms by which the
ubiquitin-proteasome degradation pathway regulates the de-
velopment, function, and degeneration of nerve terminals.
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